BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24591818)

  • 1. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids.
    Biglia N; Carinelli S; Maiorana A; D'Alonzo M; Lo Monte G; Marci R
    Drug Des Devel Ther; 2014; 8():285-92. PubMed ID: 24591818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
    Garnock-Jones KP; Duggan ST
    Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
    Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
    Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
    Donnez J; Donnez O; Dolmans MM
    Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
    Murji A; Whitaker L; Chow TL; Sobel ML
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
    Ferrero S; Vellone VG; Barra F
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
    Pourcelot AG; Capmas P; Fernandez H
    J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroid management in premenopausal women.
    Donnez J; Courtoy GE; Dolmans MM
    Climacteric; 2019 Feb; 22(1):27-33. PubMed ID: 30601065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulipristal acetate versus leuprolide acetate for uterine fibroids.
    Donnez J; Tomaszewski J; Vázquez F; Bouchard P; Lemieszczuk B; Baró F; Nouri K; Selvaggi L; Sodowski K; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):421-32. PubMed ID: 22296076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulipristal acetate: in uterine fibroids.
    Croxtall JD
    Drugs; 2012 May; 72(8):1075-85. PubMed ID: 22568731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
    Woodhead N; Pounds R; Irani S; Pradhan P
    J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
    Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
    Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
    Brazert M; Korman MP; Pawelczyk LA
    Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on medical treatment of uterine fibroids.
    Faustino F; Martinho M; Reis J; Águas F
    Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():61-68. PubMed ID: 28732252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence.
    Trefoux Bourdet A; Luton D; Koskas M
    Int J Womens Health; 2015; 7():321-30. PubMed ID: 25848323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.